TOI (The Oncology Institute) PE Ratio: At Loss (As of Jun. 26, 2026)


TOI The Oncology Institute Inc TOI
56 GF Score
Price $5.39
GF Value $2.24
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-26), The Oncology Institute's share price is $5.39. The Oncology Institute's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.37. Therefore, The Oncology Institute's PE Ratio for today is At Loss.

During the past 8 years, The Oncology Institute's highest PE Ratio was 125.86. The lowest was 0.00. And the median was 104.29.

The Oncology Institute's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.37.

As of today (2026-06-26), The Oncology Institute's share price is $5.39. The Oncology Institute's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.33. Therefore, The Oncology Institute's PE Ratio without NRI ratio for today is At Loss.

The Oncology Institute's EPS without NRI for the three months ended in Mar. 2026 was $-0.07. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.33.

During the past 3 years, the average EPS without NRI Growth Rate was 24.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -9.60% per year.

During the past 8 years, The Oncology Institute's highest 3-Year average EPS without NRI Growth Rate was 24.70% per year. The lowest was -148.40% per year. And the median was -26.55% per year.

The Oncology Institute's EPS (Basic) for the three months ended in Mar. 2026 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.37.

Back to Basics: PE Ratio


The Oncology Institute  (NAS:TOI) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


The Oncology Institute PE Ratio Related Terms


The Oncology Institute PE Ratio Historical Data

* Premium members only.

The historical data trend for The Oncology Institute's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Oncology Institute PE Ratio Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial At Loss At Loss At Loss At Loss At Loss

The Oncology Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

TOI vs CCRN, SRTA, CYH: PE Ratio Comparison

For the Medical Care Facilities subindustry, The Oncology Institute's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Oncology Institute PE Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's PE Ratio distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's PE Ratio falls into.


TOI
56GF Score
The Oncology Institute Inc TOI
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Oncology Institute PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

The Oncology Institute's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=5.39/-0.370
=-14.57(At Loss)

The Oncology Institute's Share Price of today is $5.39.
The Oncology Institute's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Is The Oncology Institute (TOI) Overvalued in 2026?

Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued. The current stock price of $5.39 is trading 140.6% above its estimated GF Value™ of $2.24. GuruFocus considers The Oncology Institute to be Significantly Overvalued.

Key valuation signals for TOI:

  • PE Ratio: At Loss
  • GF Value™: $2.24 vs. price of $5.39 (140.6% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


The Oncology Institute Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOI

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.39
Price
$2.24
GF Value